Please login to the form below

Not currently logged in
Email:
Password:

Open Health adds pH Associates to its roster

UK real world data specialist will bolster Open's market access offering

Open Health has joined forces with pH Associates in a move the London-based communications group said would bolster its existing market access offering.

pH is one of the leading 'real world data' specialists in the UK and its addition to Open Health's ranks will see it line up alongside the group's Harvey Walsh and Succinct Market Access practices.

Sandy Royden, founding partner, Open Health:"The pH Associates brand is synonymous with excellence and leadership in the real world data and market access arena, and we are delighted to have them on board. We see many synergies across both our current market access practices, but also our wider range of services.”

The pH leadership team of Kate Peperell and Lesley Howell will form a new executive board alongside Open Health's David Rowley, Sandy Royden and Roger Selman.

Peperell, joint managing director of pH Associates, said:“We are very excited to be joining the Open Health family. There has been a paradigm shift in the acceptance and demand for data throughout the product lifecycle.

“The NHS need data converting to insight and also the practical tools to help drive change. The partnership with Open will allow us to continue to meet the ever increasing demand for data and also bring tremendous value to our clients through the wider market access offering.”

Marlow-based pH was founded in 1999 and its current pharmaceutical clients include Abbott, Janssen Cilag, Novartis and Sanofi. In addition, pH also works with NHS and academic clients, including a number of Medical Royal Colleges.

The current senior management team and structure of pH will remain unchanged and there will be no changes to the existing services the company offers. Also, all contracts will remain in place

17th October 2012

From: Sales, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics